Inflammatory Myositis - Epidemiology Forecast - 2034

Key Highlights

• The analyst projects that among the total diagnosed prevalent cases of Inflammatory Myositis in 7MM approximately 49% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 68 thousand diagnosed prevalent cases of Inflammatory Myositis.
• According to the analysis, Inflammatory Myositis was diagnosed in approximately 65% of females and 35% of males within the 7MM in 2022. This analysis indicates a higher prevalence of Inflammatory Myositis among females than males.
• The highest proportion of Inflammatory Myositis cases was estimated in the 45-64 years in the 7MM, with an estimated ~78 thousand cases, while the least cases were in the age group 0-17 years (~7 thousand cases).

The “Inflammatory Myositis - Epidemiology - 2034” report delivers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Diagnostic Algorithm

Inflammatory Myositis Overview

Inflammatory myopathies are rare and can affect both adults and children. Patients with inflammatory myopathies typically present with sub-acute to the chronic onset of proximal weakness manifested by difficulty rising from a chair, climbing stairs, lifting objects, and combing hair, among others.

Inflammatory Myositis Diagnosis

Diagnosing inflammatory myositis is challenging, particularly in the early stages when the symptoms are nonspecific. Diagnosis of inflammatory myositis is complicated because, despite appropriate diagnostic investigation, no uniform diagnostic criteria are available. The existing diagnostic criteria for inflammatory myositis, such as the Bohan and Peter criteria for dermatomyositis, have limitations. These criteria rely on a combination of clinical, laboratory, and histopathological features, which can be subjective and lack sensitivity and specificity. Developing updated and more refined diagnostic criteria can improve diagnostic accuracy and reduce misdiagnosis.

Currently, imaging techniques, such as magnetic resonance imaging, can assist in diagnosing inflammatory myositis by visualizing muscle inflammation. Invasive procedures, such as muscle biopsies, are currently required for definitive diagnosis of inflammatory myositis. However, there is still a need for more sensitive and specific imaging modalities that can accurately detect and quantify muscle inflammation, differentiate between different muscle pathologies, and assess disease activity. Developing noninvasive diagnostic tools, such as blood tests or imaging-based approaches, that can accurately identify and differentiate inflammatory myositis subtypes would be valuable in reducing the need for invasive procedures.

Inflammatory Myositis Epidemiology

For the purpose of designing the patient-based model for Inflammatory Myositis (OSA), the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Inflammatory Myositis, Type-specific Diagnosed Prevalent cases of Inflammatory Myositis, Gender-specific Diagnosed Prevalent cases of Inflammatory Myositis, Age-specific Diagnosed Prevalent cases of Inflammatory Myositis, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per estimations, the total diagnosed prevalent cases of Inflammatory Myositis in the 7MM were approximately 184 thousand cases in 2022 and are projected to increase during the forecast period.

• The overall count of individuals diagnosed with Inflammatory Myositis in the United States was approximately 90 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034). The anticipated future rise in Inflammatory Myositis cases may stem from factors like increased awareness, aging population, environmental triggers, genetic predisposition, autoimmune factors, improved survival, and changing lifestyles.
• Among the 7MM, EU4 and the UK accounted for nearly 37% diagnosed prevalent cases of Inflammatory Myositis, and these cases are expected to increase during the forecast period (2023-2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of Inflammatory Myositis, accounting to 32%, followed by the Italy (22%) and the UK (20%) in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In Japan, there were around 26 thousand diagnosed prevalent cases of Inflammatory Myositis in 2022. These cases are expected to increase at a significant CAGR.
• The primary types of inflammatory myositis are Polymyositis, Dermatomyositis, and Inclusion Body Myositis (IBM). Each present distinct symptoms, including muscle weakness, skin rashes, and specific patterns of muscle involvement. In 2022, within the EU4 and the UK, Polymyositis had the highest percentage, representing approximately 51% of the total diagnosed inflammatory myositis cases.
• Gender-specific diagnosed prevalent cases of Inflammatory Myositis showed that females were more affected by Inflammatory Myositis than males in the 7MM in 2022. The higher prevalence of Inflammatory Myositis in females compared to males may be attributed to hormonal influences, genetic predispositions, and differences in immune responses between sexes.
• Assessments as per estimates suggest that among age groups 0-17 years, 18-44 years, 45-64 years, and 65 years and above, a higher number of diagnosed prevalent cases of inflammatory myositis were found in the age group of 45-64 years accounting for 46% of the cases in the US, in 2022.
• The highest proportion of Inflammatory Myositis cases was estimated in the 80 years and above age group in the 7MM, while the least cases were in the age group 40-49 years. Inflammatory Myositis is highly prevalent in geriatric population, while the disease appears rare below this age group.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Inflammatory Myositis evolving diagnosis landscape, along with challenges related to accessibility, including KOL from David Geffen School of Medicine, Los Angeles, the US; University Hospital Aachen, Germany; Department of Pediatrics, Institute of Molecular Medicine, Brescia, Italy; National Institute of Allergy and Infectious Disease, Spain; Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan, and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Inflammatory Myositis, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Inflammatory Myositis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Diagnosed Prevalence of Inflammatory Myositis
• Type-specific Diagnosed Prevalence of Inflammatory Myositis
• Gender-specific Diagnosed Prevalence of Inflammatory Myositis
• Age-specific Diagnosed Prevalence of Inflammatory Myositis

Inflammatory Myositis Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• Inflammatory Myositis Epidemiology Segmentation

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Inflammatory Myositis? What will be the growth opportunities across the 7MM concerning the patient population of Inflammatory Myositis?
• What is the historical and forecasted Inflammatory Myositis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Inflammatory Myositis and why?
• What factors are affecting the diagnosis of the indication?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Inflammatory Myositis prevalence cases in varying geographies over the coming years.
• A detailed overview of Severity, Gender, and Age-specific prevalence of Inflammatory Myositis.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Inflammatory Myositis Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Inflammatory Myositis cases in 2022?

The highest cases of Inflammatory Myositis was found in the Germany among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Inflammatory Myositis cases in 2022?

The highest cases of Inflammatory Myositis were found in the US among the 7MM in 2022.